Endoscopic Submucosal Dissection vs. Transanal Endoscopic Surgery for Rectal Neoplasia

Launched by TURKISH SOCIETY OF COLON AND RECTAL SURGERY · Mar 27, 2025

Keywords

ClinConnect Summary

This clinical trial is studying two different methods for treating early-stage rectal growths, also known as rectal neoplasia. The two techniques being compared are called Endoscopic Submucosal Dissection (ESD) and Transanal Minimally Invasive Surgery (TAMIS). The goal of the trial is to see which method works better in terms of how well they remove the growths, how long the procedures take, the rates of complications, and the length of hospital stays. Researchers will follow patients for a year to gather important information about their recovery and any potential return of the growths.

To be eligible for this trial, participants need to be adults over 18 years old with specific types of growths that are larger than 2 cm and located within 15 cm from the anal opening. However, certain individuals, such as those who have had previous surgeries on the rectum or have specific medical conditions like inflammatory bowel diseases, will not be able to participate. The trial is not yet recruiting participants, but it aims to include a diverse group of patients to help find the best treatment options for this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients (\>18 years)
• • Non-pedunculated (sessile) lesions larger than 2 cm.
• • Lesions located within 15 cm from the anal verge confirmed by sigmoidoscopy or magnetic resonance imaging (MRI)
• Exclusion Criteria:
• • Evidence of lymph node involvement, T2 rectal tumors, or distant metastasis on preoperative imaging modalities (MRI, ERUS, CT)
• • Previous attempt at endoscopic resection
• • Previous rectal surgery
• • Previous pelvic radiation therapy
• • Inflammatory bowel diseases (Crohn's disease, Ulcerative colitis)